Patrick Forde, Professor at The Johns Hopkins University, shared on X:
”On other hand, a win for combined EGFR plus.
Met inhibition post progression on osimertinib and co. Important to note, 34% of pts will have an eligible MET aberration post osi, unclear how many post osi plus chemo in Flaura2.”
Patrick Forde was recognized among OncoDaily’s The 100 Most Influential People in Oncology in 2025, highlighting his contributions to the field of oncology.
Nominations for 100 Influential People in Oncology 2026 are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15: 100 Influential People in Oncology 2026 – Nominations are Open!
Other articles about cancer types on OnoDaily.